Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid
 tumours by Kosmas, C et al.
Paclitaxel (Taxol®) represents a recently established active cyto-
toxic agent against a wide variety of advanced solid tumours
including ovarian, breast, lung, head and neck cancers, etc. Both
ifosfamide and cisplatin have demonstrated activity as single
agents and in combination in a broad range of tumours both in
first-line treatment as well as in the setting of relapsed/refractory
disease.
The potential synergism of paclitaxel and agents that cause
DNA damage was evidenced by the observation that paclitaxel
enhanced radiation-induced cell death in human glioblastoma cell
lines (Tishler et al, 1992a, 1992b). In addition, several groups have
demonstrated that paclitaxel intensifies the cell-killing effects of
chemically-induced DNA damage by alkylating agents and
cisplatin, provided that paclitaxel precedes these agents. A supra-
additive cell killing effect was observed when certain cell lines
were incubated with paclitaxel combined with cisplatin (Parker et
al, 1993).
In the clinical setting, paclitaxel has shown enhanced activity
and possibly synergistic effects when combined with alkylating
agents cyclophosphamide/ifosfamide (Bunnell et al, 1998) or
cisplatin (Rowinsky et al, 1993). However, ifosfamide has shown
to synergize with platinum compounds by reversing intracellular
mechanisms of resistance that would ultimately lead to increased
DNA repair and/or detoxification of reactive intermediates of
cisplatin, such as the glutathione/thiol (GSH) systems. Depletion
of the intracellular glutathione pool by 70% has been observed in
peripheral blood lymphocytes after ifosfamide administration
(Lind et al, 1989). It is thus theoretically conceivable that the
administration of ifosfamide and cisplatin might overcome resis-
tance to cisplatin due to elevated GSH concentrations. Therefore,
given the in vitro and in vivo synergism of every selected pair of
drugs between paclitaxel, ifosfamide and cisplatin, it is expected
that the three-drug combination (given the acronym PIC by our
group) would exert a favourable cytotoxic profile against a variety
of advanced solid tumours. In addition, the safety of the 1-h pacli-
taxel infusion schedule given with short premedication, studied by
our group and other investigators, made the drug very easy to
administer in the out-patient setting, as well as allowed its incor-
poration into complex multidrug chemotherapy regimens, such as
the combination of paclitaxel, ifosfamide and cisplatin (Greco and
Hainsworth, 1995; Tsavaris et al, 1997; Tsavaris and Kosmas,
1998).
The aim of the present study was to (i) evaluate the maximum
tolerated dose (MTD) of the combination of paclitaxel–ifos-
famide–cisplatin (PIC), drugs known to possess significant single-
agent and doublet activity against a wide variety of solid tumours,
as well as carefully define dose-limiting toxicities (DLT), (ii)
obtain preliminary evidence of activity against a variety of
advanced solid tumours, (iii) examine the feasibility of out-patient
administration of a regimen containing drugs characterized for the
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preference to be given for safety in the in-patient setting, due to the
requirement of vigorous pre- and post-hydration and electrolyte
replacement, and thus reduce hospitalization costs.
PATIENTS AND METHODS
Patient selection
Patients with histologically confirmed carcinomas and no curative
option with surgery, radiation therapy, or any other chemotherapy
regimen were candidates for the present study. Eligibility
included: (i) histologically confirmed malignancy not curable by
standard chemotherapy; (ii) WHO performance status ≤ 2; (iii) life
expectancy  ³ 3 months; (iv) adequate haematopoietic (ANC >
1500 ml–1, PLT > 100 000 ml–1), liver (bilirubin < 1.5 mg dl–1,
AST/ALT < 2 ´ upper normal limit (nl), unless caused by tumour
and serum albumin > 3.0 g dl–1) and renal function (BUN and crea-
tinine < 1.5 nl; nl = 1.5 mg dl–1 in our laboratory or creatinine
clearance > 50 ml min–1); (v) no previous chemotherapy earlier
than 4 weeks from study entry (6 weeks for nitrosoureas and mito-
mycin-C); (vi) no prior treatment with taxanes or ifosfamide,
while cisplatin or carboplatin pre-treatment was allowed; (vii)
absence of active coronary artery disease (in the form of unstable
angina or myocardial infarction over the last 12 months), unstable
diabetes mellitus, or peripheral neuropathy ³ grade 2 by the NCI-
Common Toxicity Criteria (CTC); (viii) no prior irradiation to
areas encompassing > 30% of marrow-bearing bone; and (ix) pres-
ence of bi-dimensionally measurable disease outside a previously
irradiated field, unless definite evidence of progression at this site.
The study was approved by the Institutional Review Board of the
participating hospitals.
Treatment schedule
Eligible patients were entered in the dose levels as shown in Table
1. Paclitaxel (Taxol®) was administered at 135–215 mg m–2 over 
1 h by intravenous (i.v.) infusion on day 1, after premedication
consisting of dexamethasone 20 mg, dimethidene maleate
(Fenistil®) 4 mg and ranitidine 50 mg; all administered i.v. 1 h
before paclitaxel (8). Ifosfamide was administered at 4.5–6.0 g m–2
i.v. over 1 h divided between 2 days (days 1 and 2: 2.25–3.0 g m–2
per day) together with mesna uroprotection, 40% of the ifosfamide
dose, given i.v. before, at 3 and 6 h after ifosfamide. Cisplatin
80–100 mg m–2 i.v. over 30 min divided between 2 days (days 1
and 2: 40–50 mg m–2 per day) with adequate vigorous pre- and
post-hydration, furosemide and electrolyte replacement; 20 mEq
potassium chloride and 8 mEq magnesium sulphate per litre of
post-hydration solution (0.9% normal saline (N/S) or 1/2 N/S +
5% dextrose (D5/W)).
Supportive care
Standard anti-emetic medication included ondansetron 24 mg i.v.
1 h before chemotherapy, at 12 h 8 mg orally on days 1 and 2 and
post-chemotherapy 8 mg three times a day orally on days 3–5.
Dexamethasone 20 mg i.v. was administered 1 h before
chemotherapy (day 1 as taxol premedication as well) on days 1
and 2 and post-chemotherapy 4 mg three times a day or methyl-
prednisolone 16 mg twice a day orally on days 3–5 (Tsavaris et al,
1998). Haematopoietic growth factors included granulocyte
colony-stimulating factor (G-CSF; lenograstim) 5 mg kg–1 subcuta-
neously (s.c.) from day 4 until WBC ³ 10 000 ml–1 (all except the
first three patients at DL-I).
Dose escalation schedule, DLTs and dose
modifications
Dose-limiting toxicity (DLT) was defined as follows: (i) grade 4
neutropenia of > 7 days duration; (ii) any episode of febrile ³
grade 3 neutropenia; (iii) any episode of grade 4 thrombocytopenia
requiring platelet transfusions; (iv) any non-haematologic grade 3
or 4 toxicity excluding nausea/vomiting, musculoskeletal/arthritic
pain and alopecia. Treatment was administered up to a maximum
of 6 cycles for responding patients or those with disease stabiliza-
tion, unless unacceptable toxicity was encountered, as defined in
the previous section. Patients with progressive disease (PD) were
offered palliative treatment or alternative treatment at the discre-
tion of the treating physician.
Cohorts of five patients were entered at the dose levels shown in
Table 1. In the case that DLT was encountered (defined below) in
2/5 patients at a certain dose level, three more patients were
entered at that particular level and if ³ 1/3 met the DLT require-
ments (in total at least 3/8 patients) it was then considered that the
DLT level was reached, otherwise accrual to the next higher dose
level was undertaken. In the case that three out of the first five
patients at a certain level experienced DLT no more patients were
accrued at that level and the immediately prior dose level was
considered as the MTD.
The following guidelines were applied with respect to dose
reductions for toxicity; (i) for neutropenia meeting DLT criteria
paclitaxel and ifosfamide doses were reduced by 20% in subse-
quent cycles and if toxicity reappeared after a total of 40% reduc-
tion from the starting dose at a certain level in consecutive cycles
treatment was stopped, however, the patient was evaluable for
toxicity and response; (ii) for thrombocytopenia meeting DLT
criteria, reduction of cisplatin by 20% was applied in addition to
paclitaxel and ifosfamide dose reductions as specified for dose-
limiting neutropenia; (iii) for ³ grade 3 mucositis the doses of
paclitaxel and ifosfamide were reduced by 20% in subsequent
cycles; (iv) for neuropathy ³ grade 3 treatment was interrupted; 
(v) for renal toxicity ³ 3 grade toxicity (serum creatinine eleva-
tions > 3 ´ normal) treatment was withheld until recovery (serum
creatinine < 1.8 mg dl–1) with cisplatin and ifosfamide admin-
istered with more post-hydration, mannitol diuresis and hospital-
ization in subsequent cycles. If the glomerular filtration rate (GFR)
dropped to < 40 ml min–1, cisplatin and ifosfamide were omitted in
subsequent cycles; (vi) for ³ grade 3 central nervous system
Table 1 PIC dose levels
Drug doses
Dose level Paclitaxel (mg m–2) Ifosfamide (g m–2) Cisplatin (mg m–2)
I 135 4.5 80
II 175 4.5 80
III 175 4.5 100
IV 215 4.5 100
V 215 6.0 100
VI 200 5.0 100302 C Kosmas et al
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(CNS) toxicity (ifosfamide encephalopathy) the dose of ifosfamide
was reduced by 20% and more hydration with bicarbonates was
anticipated in subsequent cycles. In the case that encephalopathy
reappeared then ifosfamide was omitted from subsequent cycles.
In the case that blood counts had not recovered to ANC 
³1500 ml–1 and PLT ³ 100 000 ml–1 on the day of therapy, treatment
was withheld until recovery, and after a maximum delay of 2
weeks no further therapy was administered.
Pretreatment, follow-up studies and response
evaluation
Tumour measurements were performed by physical examination
and the specific radiological test that documented measurable
disease before treatment. Clinical examination, full blood counts,
biochemical tests, appropriate serum tumour marker measure-
ments and a chest X-ray were carried out before each cycle of
therapy. Blood counts were checked every 3 days after each cycle
until recovery. Evaluation of response was performed every 2
cycles of therapy. Patients experiencing toxic death despite objec-
tive responses at measurable sites would be categorized as
treatment failures. Complete remission (CR) is defined as the
disappearance of all signs and symptoms of disease for at least 1
month, with the documented disappearance of all known lesions
by physical examination, X-rays, computerized tomography (CT)
scans, bone scans and the development of no new lesions. Partial
remission (PR) indicates a decrease of 50% or greater (compared
with pretreatment measurements) in the sum of the products of the
two largest perpendicular diameters of all measurable lesions and
no concomitant growth of new lesions for at least 1 month. There
could be no deterioration of symptoms or performance status
unless secondary to drug toxicity. Stable disease (SD) indicates a
decrease of less than 50% or an increase in tumour size less than
25% over the original measurements. There could be no deteriora-
tion of symptoms or performance status unless secondary to drug
toxicity. Progressive disease (PD) was defined as an increase of
25% or greater over the original measurements in the sum of the
products of the two largest perpendicular diameters of any measur-
able lesions, and relapse was defined as occurring following a
period of response when a former lesion reappeared or enlarged as
above or a new lesion appeared.
Full-staging evaluation had to be performed, as reported above,
before treatment initiation. Follow-up disease evaluation was
performed at approximately 3-month intervals after the end of
treatment.
RESULTS
Patient characteristics
Forty-two patients were entered in the present study. Their
pretreatment characteristics are shown in Table 2, with all being
evaluable for toxicity and all but one for response. Table 3 demon-
strates the DLs studied, the number of patients enroled at each DL,
the number of patients requiring dose reductions as a result of toxi-
city and the number of evaluable courses. Seven patients required
1 or more dose reductions because of toxicity, mainly in the form of
myelosuppression; three patients – five dose reductions, peripheral
neuropathy (grade 3); three patients – two omissions of the planned
last cycle, however, no evidence of ³ grade 3 neuropathy was
encountered before cycle 4, and severe (grade 3) asthenia-fatigue;
one patient – omission of the last two cycles of PIC. No dose
reductions or schedule modifications were required for renal toxi-
city. A total of 205 courses were evaluable for toxicity. One patient
died after cycle 1 at DL-III from an acute bowel haemorrhage and
multiorgan failure despite recovering from grade 4 neutropenia
and grade 3 thrombocytopenia on day 16. The death, however, was
Table 2 Patient characteristics
Number 42
Men/women 29/13
Median age (range) 55 (25–72)
Median PS (WHO) (range) 1 (0–2)
Tumour type:
NSCLC 17
Ovarian cancer 6
H&N cancer 5
UNPC 3
UPC 2
Cervical cancer 2
Breast cancer 2
Bladder cancer 2
GCT 1
Oesophageal cancer 1
Anal canal cancer 1
Prior therapy: 27
Sx only 4
Sx + RT 3
Sx + CT 7
Sx + RT + CT 1
RT only 2
RT + CT 6
CT only 4
No of prior CT regimens:
02 4
11 7
21
NSCLC: non-small-cell lung cancer; H&N: head and neck; UNPC:
undifferentiated nasopharyngeal carcinoma; UPC: unknown primary
carcinoma; GCT: germ-cell tumour; Sx: surgery; RT: radiotherapy; CT:
chemotherapy.
Table 3 Dose-limiting toxicity (DLT) at each level
No. of patients
Total no. of
Dose level Entered With DLT Type of DLT cycles (range)
I 5 0 — 28 (4–6)
II 8 (2)a 2 FN + PLT, PNs 44 (3–6)
III 8 (2) 2 TD, PNs+m 38 (1–6)
IV 5 0 — 23 (3–6)
V 8 (2) 2 FN+PNs+m, A-F 41 (3–6)
VI 8 (1) 1 FN+A-F 37 (2–6)
aNumbers in brackets represent the number of patients that required dose
reduction in subsequent cycles as a result of toxicity. One patient at DL-III
and one at DL-V, without toxicity necessitating dose reduction, interrupted
treatment both after cycle 4 because of progressive decline in PS and grade
III asthenia-fatigue respectively. FN: febrile neutropenia, PN: peripheral
neuropathy; PNm: peripheral neuropathy motor; PNs: peripheral neuropathy
sensory; A-F: asthenia-fatigue; TD: toxic death; ‘+’ denotes more than one
DLT experienced in a certain patient.considered to be treatment-related, although large ascites and
intra-abdominal metastases were present; no post-mortem evalua-
tion was carried out. Eighteen patients did not complete the
planned cycles of therapy because of: other treatment (radio-
therapy), four patients (one each at DL-I, -III, -IV and -VI);
toxicity, three patients (one at DL-II and two at DL-V); toxic
death, one patient (at DL-III); refusal for personal reasons, four
patients (one each at DL-II, -IV, -V and -VI); PD, five patients
(two at DL-II, and one each at DL-III, -IV and -VI); and declining
PS, one patient at DL-II.
Haematological toxicity
Haematological toxicities are represented in Table 4. Grade 3 and
4 neutropenia occurred at all DLs (except for grade 4 neutropenia
in DL-I) in 49% of treatment courses. However, grade 4
neutropenia whenever encountered did not exceed 5 days, thus,
never meeting the definition of DLT requirements (> 7 days’ dura-
tion) in the absence of fever. G-CSF was administered in all
patients except the first three at DL-I in cycles 1/2 only and, it was
soon realized, as a result of grade 3 neutropenia, that substantial
dose escalation at higher DLs could not be envisaged without G-
CSF support. A total of five courses (2.5%) in three patients were
associated with febrile neutropenia at DL-II, -V and -VI. The
neutrophil nadir was consistently observed between days 8 and 12.
Grade 3/4 thrombocytopenia was rare (7% of courses) and in only
one occasion PLT transfusions were required (PLT < 5000 ml–1
without bleeding). Severe anaemia (grade 3/4) was observed
during 13% of courses with 5% requiring transfusions of packed
red cells.
Non-haematological toxicities
Non-haematological toxicities are shown in detail in Table 5. The
major non-haematological toxicity encountered was a peripheral
sensorimotor neuropathy. It was rarely severe; grade 3 in 7% of
patients and no case of grade 4, but commonly grade 2 (55%).
Peripheral neuropathy tended to be cumulative in nature and
observed over the last three cycles, with one patient experiencing
grade 3 neuropathy after the last treatment course, while another
with a relapsed GCT treated at DL-V (prior exposure to a dose
intensive cisplatin/vincristine regimen and high cumulative
cisplatin dose) developed it soon after cycle 3, but recovered to
grade 2 after 1 month. Most patients, including those with grade 2
neuropathy, found this the most troublesome of all effects. Other
toxicities of less importance included: very mild mucositis, 8%
grade 2 and 0% grade 3/4 (particularly in head and neck (H&N)
cancer patients with prior irradiation to these sites); controllable
nausea and vomiting, 9% grade 3–0% grade 4, diarrhoea, 13%
grade 1/2 only; orthostatic hypotension, 7% grade 1/2 only;
moderate hypomagnesemia, 10% grade 1/2 only; fully reversible
renal toxicity (creatinine elevations), 3.5% grade 1/2 only. CNS
toxicity related to ifosfamide was mainly grade 1 (23% of
courses), very rarely grade 2 (1%), and in one course (0.5%)
reached grade 3 in a patient with GCT who developed concur-
rently a grade 2 creatinine elevation and grade 3 peripheral
neuropathy after cycle 3, that was fully reversible. Myalgias and
arthralgia potentially attributable to either G-CSF or paclitaxel
were of grade 1/2 severity in 59% of cycles, starting at least 48 h
after paclitaxel and lasting up to 3–4 days, but rarely posed a
significant problem apart from patient anxiety. Alopecia was very
common (86% of patients) and occurred at all DLs. Skin toxicity
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Table 4 Haematological toxicity (HT)
Dose Level
I II III IV V VI Total
No. of assessable patients 588588 4 2
Courses assessable for HT 28 38 38 23 41 37 205
(range/patient; median) (4–6; 6) (3–6; 4) (1–6; 5) (3–6; 4) (3–6; 6) (2–6; 6)
No. of courses with (%):
Leukopenia G1 6 (21) 16 (42) 8 (21) 8 (35) 8 (20) 8 (22) 54 (26)
G2 0 (0) 7 (18) 2 (5) 0 (0) 1 (2) 11 (30) 21 (10)
G3 9 (32) 6 (16) 10 (26) 3 (13) 13 (32) 9 (24) 50 (24)
G4 0 (0) 4 (11) 7 (18) 4 (17) 10 (24) 0 (0) 25 (12)
Neutropenia G1 7 (25) 7 (18) 2 (5) 7 (30) 2 (5) 6 (16) 31 (15)
G2 1 (4) 4 (11) 4 (11) 1 (4) 4 (10) 7 (19) 21 (10)
G3 7 (25) 6 (16) 7 (18) 5 (22) 13 (32) 8 (22) 46 (22)
G4 2 (7) 10 (26) 15 (39) 5 (22) 13 (32) 10 (27) 55 (27)
Thrombocytopenia G1 2 (7) 8 (21) 13 (32) 1 (4) 9 (22) 14 (38) 46 (22)
G2 9 (32) 7 (18) 4 (11) 3 (13) 4 (10) 7 (19) 7 (19)
G3 2 (7) 1 (3) 2 (5) 4 (17) 4 (10) 0 (0) 13 (6)
G4 0 (0) 3 (8) 0 (0) 0 (0) 0 (0) 0 (0) 3 (1)
Anaemia G1 7 (25) 11 (29) 7 (18) 11 (48) 20 (49) 19 (51) 75 (37)
G2 4 (14) 4 (11) 8 (21) 2 (9) 14 (34) 5 (14) 37 (18)
G3/4 2 (7) 7 (18) 6 (16) 1 (4) 7 (17) 4 (11) 27 (13)
a{[Anaemia ³ G3
(after cycle 4)] — 0 (0) 1 (12.5) 1 (12.5) 1 (20) 3 (37.5) 1 (12.5) —}
Transfusions of
pRBCs 1 (4) 0 (0) 4 (11) 0 (0) 4 (10) 2 (5) 11 (5)
Febrile neutropenia 0 (0) 2 (5) 0 (0) 0 (0) 2 (5) 1 (3) 5 (2.5)
pRBCs: packed red blood cells; G1–4: Grades 1–4.
aDenotes number of patients with ³ G3 anaemia after cycle 4 (cumulative anaemia).was mild and consisted of increased thickening and facial folding,
while no eruptions or rashes and discoloration were observed. A
significant toxicity reported by most patients was asthenia/fatigue,
occurring in the majority of patients (grade 1 = 45%, grade 2 =
33%, grade 3 = 7%) at almost all DLs, being cumulative in nature,
particularly after cycle 4. Paclitaxel-related hypersensitivity reac-
tions were observed in two cases and consisted of very mild facial
flushing of brief duration that did not necessitate drug discontinu-
ation.
Responses
Major responses (CR/PR) were seen in 47.5% of patients, particu-
larly those with NSCLC; 53%, OC; 50%, H&N cancer (with
UNPC); 65% (Table 6). It should be noted that many patients were
pretreated by chemotherapy and/or radiotherapy (RT) (Table 2).
Two NSCLC patients with brain metastases were treated with PIC
before cranial RT and had a near CR. All but one ovarian cancer
(OC) patient were pretreated with carboplatin ± cyclophos-
phamide, while 4/5 H&N and 2/3 UNPC patients had prior chemo-
RT.
DISCUSSION
The rationale for combining paclitaxel, ifosfamide and cisplatin
derives from both in vitro data and theoretical assumptions based
on the properties of each individual cytotoxic agent to mediate its
cellular damage. In brief, paclitaxel inhibits the energy-dependent
enzymatic reactions, by disengaging activated intracellular phos-
phate (e.g. ATP and GTP), required for the repair of the DNA
304 C Kosmas et al
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Table 5 Non-haematological toxicity (NHT)
Dose Level
I II III IV V VI Total
No. of assessable patients 5 8 8 5 8 8 42
Courses assessable for NHT 28 38 38 23 41 37 205
(range/patient; median) (4–6; 6) (3–6; 4) (1–6; 5) (3–6; 4) (3–6; 6) (2–6; 6)
No. of courses with (%):
Nausea & vomiting G1 12 (43) 20 (53) 23 (61) 4 (17) 8 (20) 18 (49) 72 (37)
G2 2 (7) 0 (0) 8 (21) 3 (13) 6 (15) 4 (11) 23 (11)
G3 1 (4) 0 (0) 2 (5) 6 (26) 6 (15) 4 (11) 19 (9)
G4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Mucositis G1 9 (32) 20 (53) 23 (61) 4 (17) 5 (12) 14 (38) 75 (37)
G2 3 (11) 1 (3) 5 (13) 6 (26) 1 (2) 0 (0) 16 (8)
G3/4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Diarrhoea G1 1 (4) 10 (26) 6 (16) 0 (0) 4 (10) 4 (11) 25 (12)
G2 0 (0) 0 (0) 0 (0) 0 (0) 2 (5) 0 (0) 2 (1)
G3/4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Myalgia/arthralgia G1 10 (36) 18 (47) 10 (26) 13 (57) 16 (39) 21 (57) 88 (43)
G2 0 (0) 0 (0) 15 (39) 0 (0) 3 (7) 14 (38) 32 (16)
G3/4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Orthostatic
hypotension G1 1 (4) 3 (8) 1 (3) 2 (9) 1 (2) 3 (8) 11 (5)
G2 0 (0) 0 (0) 2 (5) 0 (0) 1 (2) 1 (3) 5 (2)
G3 0 (0) 0 (0) 1 (3) 0 (0) 0 (0) 0 (0) 1 (0.5)
G4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Hypomagnesemia G1 1 (4) 3 (8) 7 (18) 2 (9) 3 (7) 1 (3) 17 (8)
G2 0 (0) 1 (3) 1 (3) 1 (4) 1 (2) 0 (0) 4 (2)
G3/4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
CNS toxicity G1 12 (43) 9 (24) 8 (21) 2 (9) 5 (12) 12 (32) 48 (23)
G2 0 (0) 1 93) 1 (3) 0 (0) 1 (2) 0 (0) 2 (1)
G3 0 (0) 0 (0) 0 (0) 0 (0) 1 (2) 0 (0) 1 (0.5)
G4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Renal G1 0 (0) 0 (0) 4 (11) 0 (0) 0 (0) 0 (0) 4 (2)
G2 0 (0) 0 (0) 1 (3) 1 (4) 1 (2.5) 0 (0) 3 (1.5)
G3/4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
No. of patients with (%):
Peripheral neuropathy G1 3 (60) 1 (12.5) 2 (25) 1 (20) 4 (50) 2 (25) 13 (31)
G2 2 (40) 6 (75) 3 (37.5) 4 (80) 3 (37.5) 5 (62.5) 23 (55)
G3 0 (0) 1 (12.5) 1 (12.5) 0 (0) 1 (12.5) 0 (0) 3 (7)
G4 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Asthenia/fatigue G1 2 (40) 4 (50) 3 (37.5) 4 (80) 1 (12.5) 2 (25) 12 (29)
G2 2 (40) 2 (25) 2 (25) 1 (20) 4 (50) 4 (50) 15 (36)
G3 0 (0) 1 (12.5) 0 (0) 0 (0) 3 (37.5) 0 (0) 4 (10)
Alopecia G1 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
G2 0 (0) 1 (12.5) 2 (25) 0 (0) 1 (12.5) 2 (25) 6 (14)
G3 5 (100) 7 (87.5) 6 (75) 5 (100) 7 (87.5) 6 (75) 36 (86)
Skin toxicity G1 2 (40) 3 (37.5) 4 (50) 1 (20) 2 (25) 3 (37.5) 15 (36)
G2 1 (20) 1 (12.5) 0 (0) 1 (20) 0 (0) 0 (0) 3 (7)
G3 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)damage induced by cisplatin (causing kinking of the DNA double
helix) and oxazaphosphorine (cyclophosphamide and ifosfamide)
alkylating agents (prevention of DNA strand preparation and
unwinding). These different types of DNA lesion caused by
cisplatin and oxazaphosphorine cytostatics are repaired by the
nucleotide excision repair pathway (ERCC and XP genes) and the
mismatch repair pathway (HNPCC gene) (Reed et al, 1995). In
vitro synergism has been demonstrated between paclitaxel and
hydroperoxy-ifosfamide, an activated ifosfamide metabolite,
against cisplatin-sensitive and -resistant OC cell lines (Klaassen et
al, 1996). This synergism appears to be sequence-dependent and
exerted when paclitaxel preceded hydroperoxy-ifosfamide or
when exposure to these drugs was simultaneous. In contrast, when
exposure to hydroperoxy-ifosfamide preceded that of paclitaxel,
clear in vitro antagonism was demonstrated, a finding confirmed
with other alkylating agents (Kennedy et al, 1994; Liebmann et al,
1994). As discussed earlier, the synergistic interaction between
paclitaxel and DNA-damaging agents is based on the ability of
paclitaxel to slow the DNA repair processes. This might explain
the importance of administering paclitaxel before the DNA-
damaging agent.
Based on these preclinical in vitro experimental data, we believe
that the sequence and infusion times regarding paclitaxel, ifos-
famide and cisplatin, as applied in the present study, might lead to
potential in vivo synergism between the three drugs. Ifosfamide
and cisplatin given alone on day 2 of our treatment schedule
should still be modulated by paclitaxel’s sustained activity given
only on day 1 by 1 h short infusion. After short 1- and 3-h pacli-
taxel infusion schedules biologically relevant concentrations 
(³ 0.1 mmol l–1) of the drug are still present at 24-h post-infusion
and are rather adequate in inducing pertinent antimicrotubule
effects (Kearns et al, 1995). Therefore, synergism between pacli-
taxel and ifosfamide-cisplatin should apparently be effected over
both days of our treatment schedule.
If the above considerations regarding sequence-dependent inter-
actions for optimal drug scheduling are important in order to
maximize efficacy, of equal importance are the effects of drug
sequencing related to bone marrow toxicity. Data from phase I
clinical studies of the paclitaxel/cyclophosphamide combination
employing different schedules of drug administration demon-
strated variable haematologic toxicity. The highest degree of
haematologic toxicity was encountered when paclitaxel was
administered by 24-h or 72-h continuous infusion with high doses
of cyclophosphamide (Kennedy et al, 1994; Tolcher, 1996).
However, when paclitaxel, given by 3-h infusion, was followed 
by cyclophosphamide, bone marrow toxicity was of much less
severity (Pagani et al, 1997). Toxicity with the paclitaxel/
cyclophosphamide combination appears to be lessened when
paclitaxel follows cyclophosphamide. Similarly, with the
docetaxel/ifosfamide combination, the sequence of giving the
taxane first led to a higher MTD than the reverse (Pronk et al,
1998). However, sequence dependence may be less apparent with
concurrent or near-concurrent administration of paclitaxel and
cyclophosphamide, as it appears to be the case with the short pacli-
taxel infusion schedules (Pagani et al, 1997). It is therefore real-
istic to consider that the almost concurrent administration of
paclitaxel and ifosfamide followed by cisplatin could account for
the tolerable haematologic toxicity, i.e. neutropenia and thrombo-
cytopenia, encountered in our study up to high individual drug
doses given at DL-V. At the highest DL, such doses of ifosfamide
(6 g m–2) and cisplatin (100 mg m–2) when combined with other
myelotoxic drugs, like etoposide, are associated with a high inci-
dence of thrombocytopenia. The very low incidence of grade 4
platelet toxicity even at these doses combined with paclitaxel 
215 mg m–2 might imply a megakaryocyte or marrow progenitor
cell sparing effect exerted by paclitaxel, closely similar to the situ-
ation postulated to occur when paclitaxel is combined with carbo-
platin, a classic platelet cytotoxin (Huizing et al, 1997).
Neurotoxicity, in the form of peripheral neuropathy, is antici-
pated to be the principal non-haematologic toxicity when evalu-
ating paclitaxel–cisplatin combinations. In our study, only three
cases of grade 3 peripheral neuropathy were recorded, one each at
DL-II, DL-III and DL-V, principally consisting of severe dysaes-
thesias in two patients, loss of proprioception in one patient, while
all patients developed motor dysfunction as well as numbness,
burning and parasthesias. It should be noted that 2/3 of these
patients were pre-treated with potent neurotoxic drugs; a woman
with a relapsed cervical carcinoma had received prior
chemotherapy with a weekly combination of bleomycin,
vincristine and cisplatin (BOP regimen) ´ 4 weeks and a man with
relapsed GCT had been pretreated with the intensive BOP-BEP
regimen for high-risk GCTs (Horwich et al, 1994), both incorpo-
rating aggressive cisplatin and vincristine dosing. Peripheral
neuropathy appeared to be cumulative in nature, usually occurring
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Table 6 Response to treatment; total and by tumour type
Response to treatment (PIC)
No of patients (%)
Tumour type No of patients CR PR SD PD
NSCLC 17 1 (6) 8 (47) 6 (35) 2 (12)
Ovarian cancer 6 2 (33) 1 (17) 2 (33) 1 (17)
H&N cancer 5 – (0) 3 (60) 2 (40) – (0)
UNPC 3 – (0) 2 (67) 1 (33) – (0)
UPC 2 – (0) – (0) 1 (50) 1 (50)
Cervical cancer 2 – (0) – (0) 2 (100) – (0)
Breast cancer 2 – (0) 1 (50) – (0) 1 (50)
Bladder cancer 2 – (0) 1 (50) 1 (50) – (0)
GCT 1 – (0) 1 (100) – (0) – (0)
Oesophageal cancer 1 – (0) – (0) 1 (100) – (0)
Anal canal cancer 1 – (0) – (0) 1 (100) – (0)
Total 42 3 (7) 17 (40.5) 17 (40.5) 5 (12)after cycle 4 or after the end of the planned six courses. Of the
above three patients, who developed severe neuropathy, one did so
after cycle 4 (DL-II), one after cycle 6 (DL-III) and the patient
with GCT treated at the highest DL (DL-V) after cycle 3, most
likely due to his prior exposure to multiple cycles of high-dose
cisplatin and vincristine (BOP-BEP regimen). These are close to
the toxicity levels achieved with the paclitaxel/cisplatin combina-
tion at 250/75 mg m–2 (Rowinsky et al, 1993). In this landmark
analysis of neurotoxicity, regarding the paclitaxel/cisplatin combi-
nation, it became apparent that peripheral neuropathy was cumula-
tive in nature and evident after 4–6 cycles, but at the highest
paclitaxel dose levels (³ 250 mg m–2) the onset of toxicity was
usually abrupt and appeared relatively early (after 1–2 cycles).
Cisplatin appears to aggrevate the neuropathy caused by pacli-
taxel, since combinations of carboplatin and paclitaxel have 
shown a lower degree of peripheral neuropathy compared to pacli-
taxel/cisplatin. Moreover, cisplatin on its own has demonstrated a
dose-dependent neurotoxicity profile with most episodes occur-
ring at doses ³ 100 mg m–2. It is therefore possible in our study,
combining cisplatin 100 mg m–2 (at ³ DL-III), to produce signifi-
cant peripheral neuropathy even at lower paclitaxel doses than the
ones leading to toxicity when combined with cisplatin 75 mg m–2
(Rowinsky et al, 1993). However, as peripheral neuropathy
appeared late during or after the entire treatment course, it did not
constitute a formal dose-limiting factor, precluding further dose
escalation in our phase I study. Given that certain patients did not
complete the full treatment course for reasons other than periph-
eral neuropathy (other therapeutic modality, disease progression,
etc.), the incidence of neurotoxicity may have been underesti-
mated in the present study. We think that care should be given with
the current combination to patients with prior exposure to neuro-
toxic drugs, elderly persons (> 60 years), and those with a history
of diabetes, chronic alcoholism and medical disorders associated
with peripheral neuropathy. Therefore, it would probably be
prudent to use lower drug doses when treating patients at risk for
developing substantial neurotoxicity.
Despite the absence of dose-limiting neutropenia and/or
thrombocytopenia at DL-V precluding further dose escalation, it
became apparent that we were reaching the limits of the regimen
given the occurrence of cumulative anaemia and asthenia, usually
after cycle 4, at this DL. Therefore, we did not feel it realistic to
attempt further dose escalation. A more reasonable DL for further
phase II testing in non-pretreated patients would be DL-VI, which
does not result in significant toxicities or asthenia with decline in
PS.
Preliminary results of the current combination with either
cisplatin or carboplatin have been reported by various investiga-
tors (Palackdhary, 1997; Zaniboni et al, 1997; Bajorin et al, 1998;
Shin et al, 1998; Zanetta et al, 1998). All but one study have not
attempted defining DLTs and have chosen arbitrarily doses of
drugs much lower than those reached in our study (Palackdhary,
1997). In that study, where a formal phase I design was under-
taken, only very preliminary results in ten patients have been
presented.
Despite the fact that tumour response was not the primary objec-
tive of the present study a 47.5% response rate was encountered
(Table 6), with many responding patients having had failed prior
chemotherapy ± RT. Responses were seen in NSCLC, OC and H&N
cancer patients. Similarly, high response rates have been observed
by other investigators in H&N cancer (Shin et al, 1998), bladder
cancer (Bajorin et al, 1998), cervical cancer (Zanetta et al, 1998),
NSCLC (Zaniboni et al, 1997) and GCTs (Motzer et al, 1997). A
preliminary phase I/II study of docetaxel–ifosfamide–cisplatin has
yielded encouraging results in NSCLC (Donnellan and Crown, 1997).
In conclusion, the current phase I trial of PIC combination has
demonstrated the feasibility of the regimen in the out-patient
setting, at high individual drug doses, and a promising preliminary
activity profile against a variety of advanced solid tumours.
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